Even before the trial disappointment, Novo Nordisk was facing slowing sales growth for its best-selling Wegovy and Ozempic ...

Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...